Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03549000 · ClinicalTrials.gov registry record · Phase 1
A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.
A Phase 1 study, sponsored by Novartis Pharmaceuticals.
- Terminated
- Registry status
- Phase 1
- Development phase
- 127
- Enrollment target
NCT03549000 is a Phase 1 study that was terminated before completion, run by Novartis Pharmaceuticals. The registered enrollment target is 127 participants.
The verdict
NCT03549000, a Phase 1 study, was terminated before completion, sponsored by Novartis Pharmaceuticals.
- TERMINATED
- Registry status
- Phase 1
- Development phase
- 127 participants
- Enrollment target
Study Summary
The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
Interventions
- DRUG NIR178
- OTHER NZV930
- OTHER PDR001
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 127 participants |
| Start Date | 2018-07-18 |
| Est. Completion | 2022-10-17 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT03549000
The ClinicalTrials.gov registry entry for NCT03549000 describes a study currently listed as terminated, categorized as Phase 1. The registered enrollment target is 127 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Novartis Pharmaceuticals, which has 1,375 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which NIR178 is the first listed.
NCT03549000 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT03549000 about?
NCT03549000 is a clinical study titled "A Phase I/Ib Study of NZV930 Alone and in Combination With PDR001 and /or NIR178 in Patients With Advanced Malignancies.". The purpose of this study was to assess the safety, tolerability, and preliminary anti-tumor activity of experimental medication NZV930 alone and when combined with PDR001 and/or NIR178, in patients with advanced cancers
What is the current status of trial NCT03549000?
This trial is currently terminated. It is a Phase 1 study. The enrollment target is 127 participants. The study started on 2018-07-18. Estimated completion is 2022-10-17.
What interventions are being tested in trial NCT03549000?
The interventions under investigation include: NIR178 (DRUG), NZV930 (OTHER), PDR001 (OTHER).
Who is sponsoring clinical trial NCT03549000?
This trial is sponsored by Novartis Pharmaceuticals, which has 1,375 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.